Ralaniten triacetate

Ralaniten triacetate (EPI-506), the pro-agent of Ralaniten, is a first-in-class, orally active androgen receptor (AR) N-terminal domain (NTD) inhibitor. Ralaniten triacetate shows activity against both full length and resistance-related AR species, including AR-v7[1][2].

Product Specifications

CAS Number

[1637573-04-6]

Product Name Alternative

EPI-506

UNSPSC

12352005

Target

Androgen Receptor

Type

Reference compound

Related Pathways

Vitamin D Related/Nuclear Receptor

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/ralaniten-triacetate.html

Purity

98.79

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CC(C(C=C1)=CC=C1OC[C@@H](CCl)OC(C)=O)(C(C=C2)=CC=C2OC[C@H](OC(C)=O)COC(C)=O)C

Molecular Formula

C27H33ClO8

Molecular Weight

521.00

References & Citations

[1]Obst JK, et al. Revealing Metabolic Liabilities of Ralaniten To Enhance Novel Androgen Receptor Targeted Therapies. ACS Pharmacol Transl Sci. 2019;2 (6) :453-467. Published 2019 Sep 26.|[2]Chi, Kim Nguyen et al. Efficacy, safety, tolerability, and pharmacokinetics of EPI-506 (ralaniten acetate), a novel androgen receptor (AR) N-terminal domain (NTD) inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC) progressing after enzalutamide and/or abiraterone. Journal of Clinical Oncology 35 (2017) : 5032-5032.